On Oct 31, major Wall Street analysts update their ratings for $Alignment Healthcare (ALHC.US)$, with price targets ranging from $8 to $14.
BofA Securities analyst Adam Ron maintains with a buy rating.
Barclays analyst Andrew Mok CFA maintains with a sell rating, and adjusts the target price from $7 to $8.
TD Cowen analyst Ryan Langston maintains with a buy rating, and maintains the target price at $13.
Piper Sandler analyst Jessica Tassan maintains with a buy rating, and adjusts the target price from $10 to $14.
Furthermore, according to the comprehensive report, the opinions of $Alignment Healthcare (ALHC.US)$'s main analysts recently are as follows:
Alignment Healthcare's Q3 results demonstrated outperformance through revenue growth, improved SG&A leverage, and an increase in absolute profit. This performance has bolstered confidence in the company's potential for a profitability inflection point.
Following the Q3 report, there has been an anticipation of a higher medical loss ratio due to the growth of new members and clinical initiatives, which has led to a slight reduction in the 2024 EBITDA forecast.
Here are the latest investment ratings and price targets for $Alignment Healthcare (ALHC.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
